Used in the synthesis of pharmaceutical intermediates, particularly in the development of kinase inhibitors for targeted cancer therapies. Its structure supports binding to specific enzyme active sites, making it valuable in drug discovery for oncology. The hydroxymethyl pyrrolidine and chloro-methoxy benzyl groups enhance solubility and receptor selectivity, improving pharmacokinetic properties in final drug compounds. Commonly employed in research settings for optimizing potency and reducing off-target effects in small molecule therapeutics.